Background:
Chronic kidney disease (CKD) has an impact on bone development, modeling, and remodeling. Assessment of bone health is a key element in the management of CKD. In clinical practice, serum biochemical markers [calcium, phosphate, intact parathyroid hormone (iPTH), and alkaline phosphatase (ALP)] are utilized as surrogate markers of bone health and its management.
Objective:
To assess the relationship of serum calcium, phosphate, iPTH, and ALP with bone mineral density (BMD) in children with advanced CKD (stages 3–5D).
Materials and Methods:
This cross-sectional study was carried out in a tertiary care hospital in Bangladesh from March 2022 to March 2023. A total of 45 children with advanced CKD (stages 3–5D) were included in the study. Serum calcium, phosphate, iPTH, and ALP were measured and BMD of the lumbar spine and femoral neck was measured using dual-energy X-ray absorptiometry.
Results:
A total of 45 patients were studied. Serum biochemical markers (calcium, phosphate, iPTH, and ALP) showed significant changes in CKD stages 5 and 5D (P = 0.03, P = 0.04, P = 0.001, and P = 0.014, respectively). No significant change was found in the BMD Z-score among different stages of CKD. Serum biochemical markers did not show any significant correlation with BMD Z-score except serum calcium and Z-score of the right femoral neck (ρ = 0.313, P = 0.039) and between serum ALP and both femoral necks (ρ= −0.393, P = 0.008 and ρ = −0.312, P = 0.037). However, in multivariate regression, only serum ALP was significantly correlated with BMD.
Conclusions:
Serum biochemical markers of CKD-mineral and bone disorder, that is, serum calcium, phosphate, and iPTH, are not good indicators of BMD in children with advanced CKD whereas ALP can predict the BMD.